Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NDI-101150 |
Trade Name | |
Synonyms | NDI 101150|NDI101150 |
Drug Descriptions |
NDI-101150 inhibits hematopoietic progenitor kinase 1 (HPK1; MAP4K1), which may prevent immunosuppression in the tumor microenvironment, potentially inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells and resulting in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3083); NCI Thesaurus). |
DrugClasses | MAP4K1 Inhibitor 7 |
CAS Registry Number | NA |
NCIT ID | C190694 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
NDI-101150 | NDI-101150 | 0 | 1 |
NDI-101150 + Pembrolizumab | NDI-101150 Pembrolizumab | 0 | 1 |